Want to see AU:MVP full AI Analyst Report?
Top Page
Medical Developments International Limited
(Sydney:MVP)
Select Model
Select Model
Rating:64Neutral
Price Target:
AU$0.40
▼(-13.91% Downside)
Action:Reiterated
Date:08/28/26
The score is driven primarily by improved financial performance and strong balance-sheet flexibility, supported by a mostly positive earnings call highlighting growth in Pain Management and key Penthrox milestones. Offsetting these positives are a demanding valuation (high P/E), mixed technical positioning (near neutral), and guidance noting several non-recurring FY2026 benefits and identifiable FY2027 headwinds (amortization, segment weakness, and external uncertainties).
Positive Factors
Pain Management Growth
Strong Pain Management growth across Europe and Australia indicates expanding demand for Penthrox in established healthcare channels. Broad volume gains, including higher hospital usage, support a more durable growth base than reliance on a single market or customer segment.
Negative Factors
Respiratory Weakness
The Respiratory segment is currently a structural drag on consolidated growth, with weakness in the United States offsetting gains elsewhere. Continued softness would reduce the benefit of Pain Management momentum and could limit operating leverage across the broader product portfolio.
Read all positive and negative factors
Positive Factors
Negative Factors
Pain Management Growth
Strong Pain Management growth across Europe and Australia indicates expanding demand for Penthrox in established healthcare channels. Broad volume gains, including higher hospital usage, support a more durable growth base than reliance on a single market or customer segment.
Read all positive factors
Medical Developments International Limited (MVP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$41.12M
Dividend Yield0.49%
Average Volume (3M)178.04K
Price to Earnings (P/E)65.2
Beta (1Y)1.43
Revenue Growth8.99%
EPS Growth450.00%
CountryAU
Employees68
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)<0.01
Shares Outstanding112,658,325
10 Day Avg. Volume270,219
30 Day Avg. Volume178,039
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)0.80
Price to Sales (P/S)1.05
P/FCF Ratio8.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside117.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$45.95M
Medical Developments International Limited Business Overview & Revenue Model
Company Description
Medical Developments International Limited (MDIL) specializes in the development and provision of essential emergency medical solutions, serving global markets including Australia, Europe, and the United States. The company's operations are divide...
How the Company Makes Money
Medical Developments International Limited makes money primarily by selling its products—most notably Penthrox (methoxyflurane) inhalation analgesic—into healthcare channels in Australia and internationally. Revenue is generated through (1) produc...
Medical Developments International Limited Earnings Call Summary
Earnings Call Date:Aug 19, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Feb 25, 2027
Earnings Call Sentiment Positive
The call conveyed a predominantly positive operating and strategic story: solid group revenue growth (+9%), strong Pain Management performance (+21%) and multiple high-impact milestones for Penthrox (European pediatric indication, published health economic and pediatric studies, PBS extension), plus materially improved free cash flow (+$5.8m) and a strengthened balance sheet ($21.4m cash). Counterbalancing these positives were a weaker Respiratory segment (–15%), one-off partner stocking and timing benefits unlikely to repeat, lower transfer prices following partner transitions (–$1.4m), FX headwinds (adverse $2.5m swing) and ongoing external uncertainties (supply chain and tariffs) as well as an expected ~$1m amortization hit in FY '27. On balance the achievements and cash/earnings improvements appear to outweigh the challenges, leaving management well positioned to pursue geographic and indication expansion while managing known near-term headwinds.Positive Updates
Group Revenue Growth
Total group revenue of $42.6 million, up 9% year-on-year, driven by strong Pain Management performance.
Negative Updates
Respiratory Segment Weakness
Respiratory revenues declined 15% year-on-year due to softer demand (particularly in the U.S.), partially offset by pricing actions and tariff refund but still a material drag on top-line growth.
Read all updates
Q4-2026 Updates
Positive
Negative
Group Revenue Growth
Total group revenue of $42.6 million, up 9% year-on-year, driven by strong Pain Management performance.
Read all positive updates
Company Guidance
Guidance for FY‑27 is for higher end‑market demand for Penthrox (supported by the European pediatric label expansion to 6+ and the newly published Australian health‑economic study) while Respiratory demand is expected to be broadly stable; management cautioned there will be no repeat of the FY‑26 partner inventory stocking benefit (c. $1.1m) or the working‑capital tailwind (FY‑26 working‑capital improvement c. $5.2m), and noted an additional amortisation charge of approximately $1.0m (capitalised European paediatric registration costs) will hit FY‑27 results; other uncertainties to monitor include Middle East supply‑chain disruption and U.S. tariffs (FY‑26 tariff refund ~ $0.4m). For context, FY‑26 delivered group revenue of $42.6m (+9%), Pain Management up 21% (Europe revenue $9.0m, in‑market volumes +18% overall with UK&I +20%, France +11%, Nordics +19%; Australia revenue $17.9m with hospital volumes at 48,000 and hospital segment +28%), free cash flow $4.2m (up $5.8m YoY) and cash of ~$21.4m — all underpinning plans to prioritise disciplined, targeted geographic and indication expansion (initially in Europe) and continued real‑world evidence generation.Medical Developments International Limited Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
80
Positive
Cash Flow
67
Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 42.57M | 39.06M | 33.15M | 32.34M | 21.94M |
| Gross Profit | 11.98M | 29.43M | 24.37M | -2.52M | -3.06M |
| EBITDA | 3.74M | 3.34M | -29.45M | -4.28M | -12.86M |
| Net Income | 626.00K | 94.00K | -40.99M | -5.61M | -12.41M |
Balance Sheet | |||||
| Total Assets | 68.58M | 66.40M | 59.16M | 109.49M | 101.36M |
| Cash, Cash Equivalents and Short-Term Investments | 21.37M | 17.84M | 9.73M | 24.66M | 20.40M |
| Total Debt | 1.67M | 1.99M | 2.29M | 2.56M | 2.81M |
| Total Liabilities | 12.77M | 11.29M | 13.43M | 28.17M | 44.06M |
| Stockholders Equity | 55.81M | 55.10M | 45.73M | 81.31M | 57.30M |
Cash Flow | |||||
| Free Cash Flow | 5.27M | -486.00K | -13.95M | -24.16M | -15.94M |
| Operating Cash Flow | 5.75M | -43.00K | -10.78M | -16.50M | -10.72M |
| Investing Cash Flow | -7.79M | -1.04M | -3.17M | -7.67M | -5.21M |
| Financing Cash Flow | -798.00K | 8.68M | -807.00K | 28.06M | 142.00K |
Medical Developments International Limited Technical Analysis
Negative
0.46
Price Trends
0.44
Negative
0.44
Negative
0.43
Negative
Market Momentum
-0.02
Positive
31.95
Neutral
9.61
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVP, the sentiment is Negative. The current price of 0.46 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.44, and above the 200-day MA of 0.43, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 31.95 is Neutral, neither overbought nor oversold. The STOCH value of 9.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:MVP.
Medical Developments International Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$41.12M | 65.18 | 1.13% | 0.49% | 8.99% | 450.00% | |
53 Neutral | AU$8.30M | 0.30 | 64.70% | ― | -24.22% | ― | |
52 Neutral | AU$7.78M | 66.67 | 3.34% | ― | 121.40% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$49.68M | -13.04 | -1.67% | ― | 15.21% | -141.82% | |
46 Neutral | AU$13.25M | -2.99 | -9.80% | 10.53% | 5.74% | -222.22% | |
39 Underperform | AU$21.43M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
* Healthcare Sector Average
AU:MVP
Medical Developments International Limited
0.37
-0.33
-47.86%
AU:CAN
Cann Group
0.01
>-0.01
-16.67%
AU:EPN
Epsilon Healthcare Limited
0.02
>-0.01
-16.67%
AU:LGP
Little Green Pharma Ltd.
0.06
-0.07
-53.85%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-20.00%
AU:VIT
Cronos Australia Ltd.
0.02
-0.05
-69.23%
Medical Developments International Limited Corporate Events
Medical Developments International Sets Out 2026 Governance Framework
Oct 8, 2026
Medical Developments International has outlined its corporate governance framework for the financial year ended 30 June 2026, detailing the roles and responsibilities of its board, committees, and management. The statement highlights board indepen...
Medical Developments International Releases Comprehensive FY26 Annual Report
Oct 8, 2026
Medical Developments International Limited has released its FY26 annual report for the year ended 30 June 2026, outlining messages from the chair and CEO, a company overview, financial results, operational review, and insights into its people and ...
Medical Developments International Files Updated ASX Corporate Governance Statement
Oct 8, 2026
Medical Developments International has lodged its updated corporate governance statement for the year ended 30 June 2026 with the ASX, confirming it is published on the company’s website and current as at 30 June 2025. The filing, accompanie...
Medical Developments International Lets Over 1.1m Performance Rights Expire
Sep 29, 2026
Medical Developments International has notified the market of the cessation of 1,115,032 performance rights, recorded under the ASX code MVPAD. The rights lapsed on 24 September 2026 due to expiry without being exercised or converted, leading to a...
Medical Developments Sets AGM Date and Director Nomination Deadline
Sep 17, 2026
Medical Developments International Ltd, an Australian provider of emergency medical solutions, specialises in emergency pain relief and respiratory products, led by its non-opioid pain treatment Penthrox. The product is used extensively in hospita...
Medical Developments lifts FY26 profit as Penthrox gains momentum in Australia and Europe
Aug 20, 2026
Medical Developments International reported a net profit after tax of $0.6 million for FY26, up from $0.1 million a year earlier, as group revenue rose 9% to $42.6 million and free cashflow improved by $5.8 million to $4.2 million. Earnings were s...
Medical Developments International lifts profit as Penthrox expansion drives revenue growth
Aug 20, 2026
Medical Developments International reported a 9% rise in revenue to $42.6 million for the year to 30 June 2026, driven by a 21% increase in Pain Management revenue and improved pricing in Australia. Net profit after tax jumped to $0.6 million from...
Medical Developments International Sets Date for FY26 Results and Investor Webcast
Aug 12, 2026
Medical Developments International will release its financial results for the year ended 30 June 2026 on 20 August 2026, with a webcast for investors to follow later that morning featuring chief executive Brent MacGregor and chief financial office...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.